Celgene Target of Unusually High Options Trading (CELG)
Celgene (NASDAQ:CELG) was the recipient of unusually large options trading on Monday. Investors acquired 14,626 call options on the company, Analyst Ratings Net reports. This represents an increase of approximately 208% compared to the average volume of 4,747 call options.
In other Celgene news, Insider Perry A. Karsen sold 39,104 shares of Celgene stock on the open market in a transaction dated Monday, August 4th. The stock was sold at an average price of $87.55, for a total transaction of $3,423,555.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
A number of analysts have recently weighed in on CELG shares. Analysts at RBC Capital raised their price target on shares of Celgene from $95.00 to $100.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Celgene in a research note on Monday, July 28th. They now have a $92.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Celgene in a research note on Friday, July 25th. They now have a $95.00 price target on the stock, up previously from $85.00. One research analyst has rated the stock with a sell rating, three have issued a hold rating and fourteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $96.90.
Celgene (NASDAQ:CELG) traded up 1.90% on Monday, hitting $91.31. 5,321,435 shares of the company’s stock traded hands. Celgene has a 1-year low of $66.055 and a 1-year high of $92.07. The stock’s 50-day moving average is $87.37 and its 200-day moving average is $79.27. The company has a market cap of $73.003 billion and a P/E ratio of 51.79.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 24th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.01. The company had revenue of $1.87 billion for the quarter, compared to the consensus estimate of $1.85 billion. During the same quarter in the previous year, the company posted $1.52 earnings per share. The company’s revenue for the quarter was up 17.1% on a year-over-year basis. On average, analysts predict that Celgene will post $3.67 earnings per share for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.